Literature DB >> 2143771

Antibacterial activity of four cephalosporins in an experimental infection in relation to in vitro effect and pharmacokinetics.

H Mattie1, A M van Dokkum, L Brus-Weijer, A M Krul, E van Strijen.   

Abstract

The in vitro activity of four cephalosporins was compared with their effects in an experimental thigh infection (cefuroxime and cefamandole against Escherichia coli and cefamandole, ceftriaxone, and ceftazidime against Klebsiella pneumoniae) in granulocytopenic mice. The effect in vitro (ER) was defined as the difference between the growth rate without antibiotic and the growth rate at the steepest part of a 3-h growth curve in the presence of an antibiotic. The relation between concentration and ER was described with the Hill equation. Using pharmacokinetic parameters of the plasma concentrations in vivo and those of the Hill equation the corresponding time course of ER was calculated and by integration with respect to time (0tERdt), an estimate was obtained of the effect on bacteria. For all four antibiotics this estimate was significantly correlated with the actual values of the effect in vivo (EN), defined as the difference in numbers of bacteria between controls and antibiotic-treated animals at 4 h.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2143771     DOI: 10.1093/infdis/162.3.717

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Comparison of the effects of aztreonam and tigemonam against Escherichia coli and Klebsiella pneumoniae in vitro and in vivo.

Authors:  M L van Ogtrop; H Mattie; H F Guiot; E van Strijen; B R Sekh; R van Furth
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Pharmacokinetic and pharmacodynamic models of antimicrobial drugs in vitro and in vivo.

Authors:  H Mattie
Journal:  Infection       Date:  1994 Nov-Dec       Impact factor: 3.553

3.  Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion.

Authors:  J W Mouton; A A Vinks; N C Punt
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

4.  The importance of pharmacokinetics and pharmacodynamics for effective treatment of infections.

Authors:  H Mattie
Journal:  Clin Investig       Date:  1993-06

5.  Pharmacokinetics-pharmacodynamics of a sordarin derivative (GM 237354) in a murine model of lethal candidiasis.

Authors:  P Aviles; C Falcoz; R San Roman; D Gargallo-Viola
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

6.  Pharmacokinetic and pharmacodynamic models of the antistaphylococcal effects of meropenem and cloxacillin in vitro and in experimental infection.

Authors:  H Mattie; L C Zhang; E van Strijen; B R Sekh; A E Douwes-Idema
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

7.  A multicentre, randomized comparative study of 500 mg versus 1,000 mg ceftazidime t.d.s. for treatment on gram-negative infections.

Authors:  H Mattie; M W Kunst; H I Schievink; P L Jonker; P de Jonge
Journal:  Infection       Date:  1995 Jul-Aug       Impact factor: 3.553

8.  Comparison of the antibacterial effects of cefepime and ceftazidime against Escherichia coli in vitro and in vivo.

Authors:  H Mattie; B A Sekh; M L van Ogtrop; E van Strijen
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

9.  Optimal times above MICs of ceftibuten and cefaclor in experimental intra-abdominal infections.

Authors:  C O Onyeji; D P Nicolau; C H Nightingale; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

10.  Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration.

Authors:  Johan W Mouton; Alexander A Vinks
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.